Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression Profiles

2018 ◽  
Vol 24 (10) ◽  
pp. 2285-2290 ◽  
Author(s):  
Raguraj Chandradevan ◽  
Tatyana Hofmekler ◽  
Kajari Mondal ◽  
Nusrat Harun ◽  
Suresh Venkateswaran ◽  
...  
Keyword(s):  
Gene Expression ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Pediatric Inflammatory Bowel Disease ◽  
Inflammatory Bowel

scholarly journals Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease

Pharmaceutics ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 77
Author(s):  
Sara Salvador-Martín ◽  
Bartosz Kaczmarczyk ◽  
Rebeca Álvarez ◽  
Víctor Manuel Navas-López ◽  
Carmen Gallego-Fernández ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Early Response ◽  
P Value ◽  
Pediatric Inflammatory Bowel Disease ◽  
Study Population ◽  
Inflammatory Bowel ◽  
Necrosis Factor

Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged < 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.

Role of intestinal gene expression profiles in the diagnosis of Inflammatory Bowel Disease

2011 ◽  
Vol 17 ◽  
pp. S65
Author(s):  
Jessica Lee ◽  
Vladimir Valtchinov ◽  
Saum Ghodoussipour ◽  
Helen Hood ◽  
Athos Bousvaros ◽  
...  
Keyword(s):  
Gene Expression ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Inflammatory Bowel

scholarly journals Gene Expression Analysis of Peripheral Cells for Subclassification of Pediatric Inflammatory Bowel Disease in Remission

PLoS ONE ◽  
2013 ◽  
Vol 8 (11) ◽  
pp. e79549 ◽  
Author(s):  
Pieter P. E. van Lierop ◽  
Sigrid M. Swagemakers ◽  
Charlotte I. de Bie ◽  
Sabine Middendorp ◽  
Peter van Baarlen ◽  
...  
Keyword(s):  
Gene Expression ◽  
Inflammatory Bowel Disease ◽  
Expression Analysis ◽  
Bowel Disease ◽  
Gene Expression Analysis ◽  
Pediatric Inflammatory Bowel Disease ◽  
Inflammatory Bowel ◽  
Peripheral Cells
Sign in / Sign up

Export Citation Format

Share Document